RareiTi NEWS

Press Releases

April 29, 2021

RareiTi Co-Founder Wendy White has joined the board of ICORD, the International Collaboration on Rare Diseases and Orphan Drugs. 

April 23, 2021

RareiTi CEO Alex Evans, RN, has become a director of the Rare Disease Nurse Network (RDNN).

April 14, 2021

Technology-enabled, data-driven Managed Access company RareiTi is pleased to announce that Heather Manna has joined the company as Director of Regulatory Affairs.

April 8, 2021

Technology-enabled, data-driven Managed Access company RareiTi is delighted to make public its Advisory Board.

October 27, 2020

Technology enabled, data-driven Managed Access company RareiTi is delighted to announce the appointment of Dr. Olivia Kessel as Chief Medical Officer.

June 17, 2020

RareiTi Inc.™, the global technology-enabled Managed Access company welcomes Alex Evans, as Chief Executive Officer (CEO).  

January 9, 2020

Wendy White and Natalie Douglas have known each other for years; Wendy was running Siren Interactive and Natalie was running IDIS and they would often find themselves working on the same compounds in the rare disease space.


December 9, 2020 /

Natalie Douglas discusses the evolving and important role that managed access plays to address serious patient needs.

January 9, 2019 /

Wendy White is a passionate and innovative leader working at the intersection of advocacy, technology, and business in the rare disease space.

White Papers

Imagine how different this journey would be if rare patients and caregivers had someone to talk to about it. Managing life with a rare disease involves a level of uncertainty. How do you create and stick to a treatment plan that is achievable?

COVID-19 Response

The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.

Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.

Follow us on:


London  •  Chicago  •  New Jersey

©2021 RareiTi